The Hospital Clínic-IDIBAPS leads the largest European study to date on liver disease
The project, funded by the European Union and endowed with a budget of 24.8 million euros, aims to identify a large set of biomarkers that allow live1
The project, funded by the European Union and endowed with a budget of 24.8 million euros, aims to identify a large set of biomarkers that allow live1
Researchers from the Hospital Clínic-IDIBAPS have published a review in Nature Reviews Clinical Oncology about the adjuvant and neoadjuvant treatment1
Endowed with €12 million, the project is coordinated by Prof. Josep M. Llovet, the head of the IDIBAPS group Translational Research in Hepatic Oncolo1
The IDIBAPS Board of Trustees has approved the creation of a new research group. The decision results from a scientific evaluation by the ad hoc comm1
IDIBAPS researchers have reviewed the role of fibroblasts, a type of cell found in the liver, in the progression of liver cancer, both hepatocellular1
Researchers from the Hospital Clínic-IDIBAPS have participated in the preparation of the new guidelines on intrahepatic cholangiocarcinoma, the secon1
The IDIBAPS researcher Josep M. Llovet has participated in the new American AASLD guidelines for the treatment of hepatocellular carcinoma, the most1
The mortality rate during the first month of infection for patients with advanced-stage hepatocellular carcinoma rose to 20.7%.
Researchers at the Hospital Clínic-IDIBAPS and the University of Barcelona have published a review article in the journal Nature Cancer in which they1
A multi-centre study, in which the Clínic-IDIBAPS participated, identified, in nearly 2,500 transplant patients, the main risk factors for the develo1